导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.26% | 2132/4773 |
| 近一周 | -1.96% | 966/5462 |
| 近一月 | -3.66% | 1892/5421 |
| 近一季 | -6.40% | 2080/5209 |
| 近半年 | -1.88% | 1716/4920 |
| 近一年 | 2.79% | 2049/4366 |
| 近两年 | 50.32% | 1455/2954 |
| 近三年 | 31.40% | 999/2253 |
| 成立以来 | 90.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.98% 2984/4961 |
13.16% 2051/5312 |
- - |
- - |
| 2025 | 20.61% 2105/4813 |
-0.69% 2358/3635 |
1.85% 2091/4076 |
18.52% 2290/4524 |
0.61% 1897/4813 |
| 2024 | 15.85% 870/3463 |
2.51% 766/2808 |
-1.34% 1041/3014 |
15.91% 1592/3129 |
-1.17% 1613/3463 |
| 2023 | -9.64% 1209/2656 |
3.67% 1151/2280 |
-4.84% 1303/2385 |
-2.73% 730/2515 |
-5.84% 1522/2655 |
| 2022 | -18.67% 741/2207 |
-14.09% 903/1919 |
7.09% 533/2016 |
-12.60% 739/2113 |
1.14% 1369/2208 |
| 2021 | 3.33% 617/1822 |
-3.24% 787/1255 |
8.43% 624/1330 |
-3.33% 631/1466 |
1.87% 767/1822 |
| 2020 | 42.99% 254/1250 |
-6.60% 498/1028 |
16.08% 458/1067 |
15.77% 196/1164 |
13.92% 322/1184 |
| 2019 | 37.30% 337/1092 |
25.53% 461/739 |
-0.44% 257/788 |
2.39% 301/850 |
7.30% 454/918 |
| 2018 | - - |
- - |
- - |
0.72% 146/660 |
-11.12% 252/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方MSCI中国A股联接C VS. 长安沪深300非周期A(740101) |